Urolithin B inhibits proliferation and migration and promotes apoptosis and necrosis by inducing G2/M arrest and targeting MMP‐2/‐9 expression in osteosarcoma cells
Journal of Biochemical and Molecular Toxicology · 2023
DOI: 10.1002/jbt.23486 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biochemical and Molecular Toxicology, 2023. Verfasst von Nahid Tajvar Nasab und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Biochemistry, School of Medicine, Birjand University of Medical Sciences, Birjand, Iran. Hauptthemen laut MEDLINE: Apoptosis, Osteosarcoma. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Birjand University of Medical Sciences.
Abstract (Originalsprache)
Osteosarcoma (OS) is the most prevalent primary bone cancer, with a high morbidity and mortality rate. Over the past decades, therapeutic approaches have not considerably improved patients' survival rates, and further research is required to find efficient treatments for OS. Data from several studies have shown that urolithin B (UB), the intestinal metabolite of polyphenolic ellagitannins, is emerging as a new class of anticancer compounds, yet its effect on OS cancer cells remains elusive. Herein, we investigated UB's antimetastatic, antiproliferative, and apoptotic effects on the MG‐63 OS cell line. Cell viability assay, annexin V/propidium iodide staining, cell cycle arrest analysis, determination of the gene expression of MMP‐2, MMP‐9, Bax, Bcl‐2, and p53 messenger RNA (mRNA), evaluation of reactive oxygen species (ROS) generation and migration, and MMP‐2 and MMP‐9 protein expression assessments were performed. UB caused late apoptosis, necrosis, G2/M arrest, and ROS generation in MG‐63 cells. It increased the mRNA expression of the p53 tumor suppressor and Bax proapoptotic genes. UB also inhibited the migration and metastatic behavior of MG‐63 OS cells by downregulating mRNA and MMP‐2 and MMP‐9 protein expression. In general, although further in vivo investigations are warranted, the current results showed that UB might be utilized as a potential novel natural compound for OS therapy due to its nontoxic, antiproliferative, and antimetastatic nature.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Biochemistry, School of Medicine, Birjand University of Medical Sciences, Birjand, Iran.
- Cardiovascular Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran.
- Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
- Department of Physiology and Pharmacology, Faculty of Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran.
- Pharmacological Research Center of Medicinal Plants, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Förderung
- Birjand University of Medical Sciences
Zitieren
APA
Tajvar Nasab, N., Jalili-Nik, M., Afshari, A. R., Rezaei Farimani, A., & Soukhtanloo, M. (2023). Urolithin B inhibits proliferation and migration and promotes apoptosis and necrosis by inducing G2/M arrest and targeting MMP‐2/‐9 expression in osteosarcoma cells. Journal of Biochemical and Molecular Toxicology. https://doi.org/10.1002/jbt.23486
Vancouver
Tajvar Nasab N, Jalili-Nik M, Afshari AR, Rezaei Farimani A, Soukhtanloo M. Urolithin B inhibits proliferation and migration and promotes apoptosis and necrosis by inducing G2/M arrest and targeting MMP‐2/‐9 expression in osteosarcoma cells. Journal of Biochemical and Molecular Toxicology. 2023. doi:10.1002/jbt.23486
BibTeX
@article{TajvarNasab2023,
author = {Tajvar Nasab, Nahid and Jalili-Nik, Mohammad and Afshari, Amir R and Rezaei Farimani, Azam and Soukhtanloo, Mohammad},
title = {Urolithin B inhibits proliferation and migration and promotes apoptosis and necrosis by inducing G2/M arrest and targeting MMP‐2/‐9 expression in osteosarcoma cells},
journal = {Journal of Biochemical and Molecular Toxicology},
year = {2023},
doi = {10.1002/jbt.23486}
}
EUVIMED